@article{c4eeff7fcef2443fad4ed1ab90c5b568,
title = "Antibodies targeting the neuraminidase active site inhibit influenza H3N2 viruses with an S245N glycosylation site",
abstract = "Contemporary influenza A H3N2 viruses circulating since 2016 have acquired a glycosylation site in the neuraminidase in close proximity to the enzymatic active site. Here, we investigate if this S245N glycosylation site, as a result of antigenic evolution, can impact binding and function of human monoclonal antibodies that target the conserved active site. While we find that a reduction in the inhibitory ability of neuraminidase active site binders is measurable, this class of broadly reactive monoclonal antibodies maintains protective efficacy in vivo.",
author = "Daniel Stadlbauer and Meagan McMahon and Turner, {Hannah L.} and Xueyong Zhu and Hongquan Wan and Carre{\~n}o, {Juan Manuel} and George O{\textquoteright}Dell and Shirin Strohmeier and Zain Khalil and Marta Luksza and {van Bakel}, Harm and Viviana Simon and Ellebedy, {Ali H.} and Wilson, {Ian A.} and Ward, {Andrew B.} and Florian Krammer",
note = "Funding Information: Washington University has filed a patent application for antibodies 1G01, 1E01, and 1G04 with A.H.E., F.K., and I.A.W. named as inventors and A.H.E., F.K., and I.A.W. have received royalties from licensing 1G01 for clinical development. F.K. is currently consulting for Avimex, GSK, Third Rock Ventures, and Pfizer and is receiving research support from Dynavax. Research support was provided in the past by GSK and Pfizer to the Krammer laboratory. The Ellebedy laboratory received funding from Emergent BioSolutions, Moderna, and AbbVie in the form of scientific research agreements that are unrelated to the data presented in the current study. The remaining authors declare no competing interests. Funding Information: This work was partially supported by the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C (F.K. and A.H.E.), NIAID Centers of Excellence for Influenza Research and Response (CEIRR) contract 75N93021C00014 (F.K.) and NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC, 75N93019C00051) (F.K., I.A.W., A.B.W., and A.H.E.). We thank the Mount Sinai Pathogen Surveillance Program for providing access to discard nasopharyngeal swab specimens. We gratefully acknowledge all data contributors, i.e., the authors and their originating laboratories responsible for obtaining the specimens, and their submitting laboratories for generating the genetic sequence and metadata and sharing via the GISAID initiative on which this research is partially based. Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2022",
month = dec,
doi = "10.1038/s41467-022-35586-7",
language = "English",
volume = "13",
journal = "Nature communications",
issn = "2041-1723",
number = "1",
}